Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
04 2019
Historique:
received: 13 11 2018
accepted: 18 01 2019
pubmed: 30 3 2019
medline: 17 3 2020
entrez: 30 3 2019
Statut: ppublish

Résumé

DSC-MR imaging using preload, intermediate (60°) flip angle and postprocessing leakage correction has gained traction as a standard methodology. Simulations suggest that DSC-MR imaging with flip angle = 30° and no preload yields relative CBV practically equivalent to the reference standard. This study tested this hypothesis in vivo. Eighty-four patients with brain lesions were enrolled in this 3-institution study. Forty-three patients satisfied the inclusion criteria. DSC-MR imaging (3T, single-dose gadobutrol, gradient recalled-echo-EPI, TE = 20-35 ms, TR = 1.2-1.63 seconds) was performed twice for each patient, with flip angle = 30°-35° and no preload (P-), which provided preload (P+) for the subsequent intermediate flip angle = 60°. Normalized relative CBV and standardized relative CBV maps were generated, including postprocessing with contrast agent leakage correction (C+) and without (C-) contrast agent leakage correction. Contrast-enhancing lesion volume, mean relative CBV, and contrast-to-noise ratio obtained with 30°/P-/C-, 30°/P-/C+, and 60°/P+/C- were compared with 60°/P+/C+ using the Lin concordance correlation coefficient and Bland-Altman analysis. Equivalence between the 30°/P-/C+ and 60°/P+/C+ protocols and the temporal SNR for the 30°/P- and 60°/P+ DSC-MR imaging data was also determined. Compared with 60°/P+/C+, 30°/P-/C+ had closest mean standardized relative CBV ( Tumor relative CBV derived from low-flip angle, no-preload DSC-MR imaging with leakage correction is an attractive single-dose alternative to the higher dose reference standard.

Sections du résumé

BACKGROUND AND PURPOSE
DSC-MR imaging using preload, intermediate (60°) flip angle and postprocessing leakage correction has gained traction as a standard methodology. Simulations suggest that DSC-MR imaging with flip angle = 30° and no preload yields relative CBV practically equivalent to the reference standard. This study tested this hypothesis in vivo.
MATERIALS AND METHODS
Eighty-four patients with brain lesions were enrolled in this 3-institution study. Forty-three patients satisfied the inclusion criteria. DSC-MR imaging (3T, single-dose gadobutrol, gradient recalled-echo-EPI, TE = 20-35 ms, TR = 1.2-1.63 seconds) was performed twice for each patient, with flip angle = 30°-35° and no preload (P-), which provided preload (P+) for the subsequent intermediate flip angle = 60°. Normalized relative CBV and standardized relative CBV maps were generated, including postprocessing with contrast agent leakage correction (C+) and without (C-) contrast agent leakage correction. Contrast-enhancing lesion volume, mean relative CBV, and contrast-to-noise ratio obtained with 30°/P-/C-, 30°/P-/C+, and 60°/P+/C- were compared with 60°/P+/C+ using the Lin concordance correlation coefficient and Bland-Altman analysis. Equivalence between the 30°/P-/C+ and 60°/P+/C+ protocols and the temporal SNR for the 30°/P- and 60°/P+ DSC-MR imaging data was also determined.
RESULTS
Compared with 60°/P+/C+, 30°/P-/C+ had closest mean standardized relative CBV (
CONCLUSIONS
Tumor relative CBV derived from low-flip angle, no-preload DSC-MR imaging with leakage correction is an attractive single-dose alternative to the higher dose reference standard.

Identifiants

pubmed: 30923088
pii: ajnr.A6015
doi: 10.3174/ajnr.A6015
pmc: PMC6461489
mid: NIHMS1524126
doi:

Substances chimiques

Contrast Media 0
Organometallic Compounds 0
gadobutrol 1BJ477IO2L

Types de publication

Journal Article Research Support, N.I.H., Extramural Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

626-633

Subventions

Organisme : NCI NIH HHS
ID : R01 CA158079
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA220378
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA082500
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA221938
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213158
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176110
Pays : United States

Informations de copyright

© 2019 by American Journal of Neuroradiology.

Références

J Magn Reson Imaging. 2000 Feb;11(2):114-9
pubmed: 10713942
Radiology. 2008 Nov;249(2):601-13
pubmed: 18780827
J Magn Reson Imaging. 2004 May;19(5):546-54
pubmed: 15112303
Radiology. 2010 Aug;256(2):575-84
pubmed: 20529987
Magn Reson Med. 1999 Dec;42(6):1072-81
pubmed: 10571928
Radiology. 2002 Mar;222(3):715-21
pubmed: 11867790
J Magn Reson Imaging. 2009 Dec;30(6):1298-308
pubmed: 19937930
AJNR Am J Neuroradiol. 2018 Nov;39(11):1981-1988
pubmed: 30309842
Magn Reson Med. 2000 Jun;43(6):845-53
pubmed: 10861879
Radiology. 2015 Jun;275(3):772-82
pubmed: 25742194
Tomography. 2017 Mar;3(1):41-49
pubmed: 28584878
AJNR Am J Neuroradiol. 2004 Oct;25(9):1524-32
pubmed: 15502131
Radiology. 2008 May;247(2):490-8
pubmed: 18349315
World Neurosurg. 2015 Jul;84(1):163-72
pubmed: 25772608
AJNR Am J Neuroradiol. 2010 Jan;31(1):40-8
pubmed: 19749223
Neuro Oncol. 2015 Aug;17(8):1148-56
pubmed: 25646027
AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7
pubmed: 22322605
Magn Reson Med. 2010 Sep;64(3):907-13
pubmed: 20806381
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21
pubmed: 14970020
Magn Reson Med. 2012 Jul;68(1):30-40
pubmed: 22114040
J Neurooncol. 2018 Jan;136(1):13-21
pubmed: 28900832
J Neurooncol. 2015 May;122(3):497-505
pubmed: 25773062
Radiology. 1994 Apr;191(1):41-51
pubmed: 8134596
Neuro Oncol. 2015 Aug;17(8):1139-47
pubmed: 25754089
AJNR Am J Neuroradiol. 2011 Feb;32(2):382-7
pubmed: 21252041
Neuro Oncol. 2014 Jun;16(6):880-8
pubmed: 24431219
AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61
pubmed: 26066626
AJNR Am J Neuroradiol. 2012 Jan;33(1):69-76
pubmed: 22095961
AJNR Am J Neuroradiol. 2018 Jun;39(6):1008-1016
pubmed: 29794239
Magn Reson Imaging Clin N Am. 2003 Aug;11(3):403-13
pubmed: 14768726
Magn Reson Imaging Clin N Am. 2016 Nov;24(4):649-670
pubmed: 27742108
AJNR Am J Neuroradiol. 2006 Apr;27(4):859-67
pubmed: 16611779
Neuro Oncol. 2012 Jul;14(7):919-30
pubmed: 22561797
AJNR Am J Neuroradiol. 2017 Mar;38(3):478-484
pubmed: 28034995

Auteurs

K M Schmainda (KM)

From the Departments of Biophysics (K.M.S., M.A.P.) kathleen@mcw.edu.
Radiology (K.M.S., S.D.R.).

M A Prah (MA)

From the Departments of Biophysics (K.M.S., M.A.P.).

L S Hu (LS)

Departments of Radiology (L.S.H., Y.Z.).

C C Quarles (CC)

Division of Imaging Research (C.C.Q., N.S., A.S.), Barrow Neurological Institute, Phoenix, Arizona.

N Semmineh (N)

Division of Imaging Research (C.C.Q., N.S., A.S.), Barrow Neurological Institute, Phoenix, Arizona.

S D Rand (SD)

Radiology (K.M.S., S.D.R.).

B Anderies (B)

Neurosurgery (B.A.), Mayo Clinic, Scottsdale, Arizona.

Y Zhou (Y)

Departments of Radiology (L.S.H., Y.Z.).

Y Liu (Y)

Division of Biostatistics, Institute for Health and Society (Y.L., B.L.), Medical College of Wisconsin, Milwaukee, Wisconsin.

B Logan (B)

Division of Biostatistics, Institute for Health and Society (Y.L., B.L.), Medical College of Wisconsin, Milwaukee, Wisconsin.

A Stokes (A)

Division of Imaging Research (C.C.Q., N.S., A.S.), Barrow Neurological Institute, Phoenix, Arizona.

G Baird (G)

Department of Diagnostic Imaging (J.L.B., G.B.), Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island.

J L Boxerman (JL)

Department of Diagnostic Imaging (J.L.B., G.B.), Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH